

P R E S S R E L E A S E

Umeå, Sweden 11 August, 2010

BioResonator IOP device receives CE-approval – European launch begins

The BioResonator tonometer has received the official CE approval required to sell the first product in the EU. The international product launch in North America and Asia has already started, and the recent CE approval means that Europe is now first in line.

”Our accurate instruments are so simple to use that we are convinced of a strong impact, primarily in the eye specialist group, but also as an important screening and follow up tool in primary care,” says Mikael Lindblad, CEO of Umeå-based company BioResonator AB.

A high IOP can be a sign of glaucoma, a disease that entails permanent damage of the optic nerve and may lead to blindness if it goes untreated. In the Western countries some six per cent of the population over 70 years of age suffers from glaucoma.¹ Today the measuring of intraocular pressure is a standard procedure carried out by eye specialists, opticians, health care centers, and private care institutions. Many people could suffer from the disease without knowing it, and are thus unlikely to seek care. The number of undetected cases may be up to 50 per cent.² People with glaucoma will need life-long care and regular measuring of IOP.

”Our IOP devices are based on a patented technology (resonance technology) and are considerably easier to use than the current, in many ways obsolete, technology which eye clinics are constrained to using today. The BioResonator IOP devices also have the advantage of working on corneas that have undergone laser surgery,” says Mikael Lindblad.

During 2010 BioResonator completed the development of the revolutionary contact tonometer ARTTM for measure of intraocular pressure (IOP). BioResonator offers two different products – the basic model ARTTM Manual, and shortly also the fully automatic model ARTTM Servo Controlled. Both are based on the same technological platform. The company has already signed contracts with distributors on many key markets.

BioResonator's business concept is to develop and market diagnostic systems based on sensor technology for the health and medical care. BioResonator is owned by LinkMed, Karolinska Development and private entities. Read more about BioResonator at www.bioresonator.com

For more information, please contact:

Mikael Lindblad, CEO, +46 730-584620

Email: mikael.lindblad@bioresonator.com

Company chairperson:

Agneta Edberg, Senior Venture Manager, LinkMed AB, +46 70-555 75 18

Email: agneta.edberg@linkmed.se

¹ Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian metaanalysis. Invest Ophthalmol Vis Sci 2006;47:4254-61.

² Ekstrom C. Prevalence of open-angle glaucoma in central Sweden. The Tierp Glaucoma Survey. Acta Ophthalmol Scand 1996;74:107-12.